Great presentation by Kara Maxwell Abramson Cancer Ctr. BasserBRCA on TP53-driven breast cancers. Very clear presentation and an amazing body of research work. #aacr24

Don't miss our next Weill Cornell Medicine Pathology #GrandRounds 'TP53-mutated #myeloid #neoplasms : Insights into disease biology and progression,' presented by Dr. Scott B. Lovitch (@slovitch ), Assoc. #Pathologist Brigham and Women's Hospital, Ass't Prof Pathology Harvard Medical School

April 15th at noon, room C-405

Actinium’s Phase 3 SIERRA trial of Iomab-B in r/r #AML patients with a TP53 mutation have been accepted for oral presentation at #EBMT24 on 4/17 at 12:39pm GMT. More insight here: bit.ly/3IYAjfh $ATNM #EBMT24

Andrew Tang of Muzumdar Lab presents an analysis of TP53 alleles in #pancreaticcancer today at 3pm PST/6pm EST. #AACR24
abstractsonline.com/pp8/#!/20272/p…
Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp

This was such an enjoyable and thought-provoking conversation—looking forward to sharing it with everyone.

Grateful for the chance to delve into this challenging and insightful article on how/when to transplant TP53 mutated AML/MDS with its author.

ashpublications.org/bloodadvances/…

Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells

Cancer Discovery Oncology Brothers OncoAlert OncoDaily #AACR24 #AACR2024 Tali Lev Elizabeth McKenna

aacrjournals.org/cancerdiscover…

#CedarsSinaiCancer at #AACR24 . Dr. Alain Mita is a co-author on the poster “Phase 1 study of MDM2 antagonist ASTX295 in patients with solid #tumors with wild-type TP53” presented today at 9:00AM PT. Cedars-Sinai Academic Medicine

At #AACR24 , Kara Maxwell, who was selected for the 2024 AACR NextGen Stars Program, presented on distinct genomic and immunologic tumor evolution in germline TP53-driven #breastcancers . Read more about her research: aacrmeetingnews.org/news/2024-next…

'In addition to demonstrating unprecedented 100% access to #BMT in Iomab-B treated patients with active r/r #AML , we are excited by the compelling outcomes in patients with a TP53 mutation in the SIERRA trial.” More details: bit.ly/3IYAjfh $ATNM #EBMT24 #Radiotherapy

TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma International Society of Gynecologic Pathologists SGO IGCS ESGO ASCO OncoAlert sciencedirect.com/science/articl…

Phase 3 SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in r/r #AML patients who otherwise would have limited treatment options and dismal prognosis. More on our targeted radiotherapy results: bit.ly/3IYAjfh $ATNM #EBMT24

At #AACR24 , Mike V. Gormally, MD PhD will present the results of a study that identified novel T cell receptors in mouse xenograft models that have the potential to eliminate TP53-mutant tumors. Memorial Sloan Kettering Cancer Center
April 7 | 1:30 p.m. – 5 p.m. PT | Section 1
buff.ly/3TQwr4O

Fellow: 78 F MPN>AML. Pancytopenia. TP53
Me: What next
Fellow: AZA+VEN
Me: Why VEN
Fellow: CR quickly
Me: MPN>AML causes ⬇️regulation of BCLXL & resistance to VEN. If Transplant is not a goal, use HMA only. Also in TP53, VEN doesn’t work
Transplant eligible: Aza+VEN reasonable

Drug Combination May Have Potential for Cancers with TP53 Mutations

cancer.gov/news-events/ca…
#CancerResearch

Nabamita Boruah, Post Doc from @kmaxwelllab, presented “Transcriptional dysregulation in germline TP53-driven breast cancers” at #AACR2024 . Dr. Kara Maxwell was senior author on this project. Abstract: spr.ly/6013weby9 AACR Penn Medicine MD

.Christine Lovly, MD, PhD raises lots of important questions here. I was asking one of my IASLC Academy mentees just yesterday how often patients get tested for co-mutations (STK11/LKB1, TP53) that may inform Tx response. The answer: we still have a long way to go. #AACR24 #LCSM

We’re excited to share our latest MDS session, chaired by Amer Zeidan MBBS,MHS ‏عامر زيدان, ft. tariqkewan, Naval Daver, M.D. & Matteo Della Porta, who take a deep dive into TP53-mutated MDS!

Click here to check out this fantastic discussion:

👉 ow.ly/oe7B50R4mHL

#MDSsm #HemOnc #ImmunoOnc

On the #AACR24 Education Program today:
- Learn about resistance to #CARTcell therapy at 10am PT in Ballroom 20 CD from Marco Ruella
- Learn about TP53 in germline genetic testing at 12:30pm PT in Room 33 from Kara Maxwell
Learn More: spr.ly/6011wOJaz

Looking forward to giving #GrandRounds on Monday at Weill Cornell Medicine Pathology and presenting our work on TP53 mutations in myeloid neoplasia. Thanks so much to Sanjay Patel, MD for inviting me!

TP53-associated early breast cancer

227 pts, mFU: 70 mo

mAge➡️37
HR+/HER2-➡️40.9%
HR+/HER2+➡️34.4%

5y RFS (HR+/HER2)➡️61.1%!!
5y radiation-induced sarcoma➡️4.8%‼️

Quite an informative analysis. Congrats to all the researchers

OncoAlert JNCI
academic.oup.com/jnci/article-a…